Major Depressive Disorder (MDD) Treatment Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
FMI Releases New Report on the <strong>Major</strong> <strong>Depressive</strong><br />
<strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong> 2016-2026<br />
November 2016<br />
Report Id : REP-GB-1314<br />
Status : Ongoing<br />
Category : Healthcare, Pharmaceuticals & Medical Devices<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved
About<br />
Future <strong>Market</strong> Insights<br />
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom<br />
research reports, and consulting services. We deliver a complete packaged solution, which<br />
combines current market intelligence, statistical anecdotes, technology inputs, valuable growth<br />
insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC,<br />
ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy,<br />
Technology, Healthcare, and Retail.<br />
We have a global presence with delivery centers across India specializing in providing global<br />
research reports and country research reports. FMI is headquartered out of London, U.K., with a<br />
state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning<br />
from every corner of the world to distill it to one thing – the perfect solution for our client.<br />
Research Capabilities<br />
Sector Coverage<br />
<br />
<br />
<br />
<br />
Customized Research<br />
Syndicated Research<br />
Investment Research<br />
Social Media Research<br />
<br />
<br />
<br />
<br />
Automotive and Transportation<br />
Electronics, Semiconductor, and ICT<br />
Retail and Consumer Products<br />
Industrial Automation and Equipment<br />
<br />
<br />
<br />
<br />
Chemicals & Materials<br />
Food and Beverages<br />
Services and Utilities<br />
Energy, Mining, Oil, and Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
2
Research Methodology (1/2)<br />
Systematic Research Approach<br />
<strong>Market</strong> profiling<br />
Formulating discussion guide<br />
Developing list of respondents<br />
Data collection<br />
Data validation<br />
4<br />
5<br />
3<br />
1<br />
2<br />
In-depth secondary research is used to<br />
ascertain overall market size, top<br />
industry players, top products, industry<br />
associations, etc.<br />
PMR formulates a detailed discussion<br />
guide to conduct expert and industry<br />
interviews<br />
PMR develops a list of industry players<br />
(manufacturers), distributors, retailers<br />
and industry experts<br />
PMR conducts interviews with industry<br />
experts, industry players, distributors<br />
and retailers<br />
Data is validated by triangulation<br />
method, wherein secondary, primary<br />
and PMR analysis contribute to the final<br />
data<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Data<br />
Collection<br />
Data Filter<br />
& Analysis<br />
Identifying key opinion leaders<br />
Questionnaire design<br />
In-depth interviews<br />
Coverage across value chain<br />
<strong>Market</strong> participants<br />
Key strengths<br />
Product portfolio<br />
Mapping as per value chain<br />
Key focus segments<br />
A<br />
Primary<br />
Research<br />
C<br />
Company<br />
Analysis<br />
Research &<br />
Intelligence<br />
SOLUTION<br />
Actionable<br />
Insights<br />
B<br />
Desk<br />
Research<br />
<br />
<br />
<br />
<br />
<br />
<br />
Business<br />
Solution<br />
Key industry experts<br />
Channel study<br />
Developments<br />
<strong>Market</strong> dynamics<br />
Products<br />
Conclusions<br />
Data analysis<br />
6<br />
Data is scrutinized using MS-Excel to<br />
obtain qualitative and quantitative<br />
insights about the industry<br />
Primary Research #<br />
Secondary Research #<br />
Paid Publications#<br />
Insights<br />
7<br />
PMR delivers industry insights and<br />
information in the required format<br />
(PDF)<br />
<br />
<br />
<br />
<br />
Linkedin<br />
Zoominfo<br />
Salesforce<br />
Avention<br />
<br />
<br />
<br />
<br />
Company websites<br />
Company annual<br />
reports<br />
White papers<br />
Financial reports<br />
<br />
<br />
<br />
<br />
Factiva<br />
GBI<br />
Genios<br />
Meltwater<br />
# includes sources of databases<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
3
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong><br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) is one of the most common mental disorder characterized by<br />
persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and<br />
normal activities. <strong>MDD</strong> is also referred as clinical depression, major depression, and unipolar depression<br />
or as recurrent depression. The common symptoms associated with this disorder include insomnia, loss<br />
of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. Increasing<br />
number of patients suffering from <strong>MDD</strong> has grabbed the attention of <strong>MDD</strong> drugs manufacturer to invest<br />
into <strong>MDD</strong> treatment market.<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Drivers and Restraints<br />
Work life imbalances due to change in life style, and increase in <strong>MDD</strong> patient pool are the key drivers<br />
expected to drive the <strong>MDD</strong> treatment market over the forecasted period. Partnerships for codevelopment<br />
and co-marketing of <strong>MDD</strong> drugs among the drug manufactures across the globe,<br />
development of new drugs, and adequate government reimbursement policies have also fueled the<br />
growth of <strong>MDD</strong> treatment market. However, stringent regulations imposed by various governments for<br />
new drug approval, patent expiries of some blockbuster drugs, risk of complications with other<br />
medications, and related side effects of <strong>MDD</strong> drugs may hinder the growth of <strong>MDD</strong> treatment market<br />
over the forecasted period.<br />
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1314<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 4
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong><br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Segmentation<br />
The global <strong>MDD</strong> treatment market is segmented based on drug type used for the treatment of <strong>MDD</strong>.<br />
Antidepressants<br />
‣ Selective Serotonin Reuptake Inhibitors (Ssris)<br />
‣ Dopamine Norepinephrine Reuptake Inhibitor<br />
‣ Serotonin Norepinephrine Reuptake Inhibitor<br />
‣ Serotonin Modulators<br />
‣ Norepinephrine-Serotonin Modulator<br />
‣ Tricyclics and Tetracyclics<br />
‣ Monoamine Oxidase Inhibitors (MAOIs)<br />
‣ Irreversible, non-selective inhibitors<br />
• Phenelzine<br />
• Tranylcypromine<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 5
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong><br />
• Isocarboxazid<br />
‣ Irreversible, MAO B selective inhibitor<br />
• Selegiline transdermal<br />
‣ Reversible, MAO A selective inhibitor<br />
• Moclobemide<br />
Atypical antidepressants<br />
Antipsychotics<br />
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1314<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Overview<br />
At present, antidepressants are most commonly used drugs for the treatment of <strong>MDD</strong>, and has the<br />
largest market segment. <strong>Major</strong> brands of SSRI’s include Citalopram, Escitalopram, Fluoxetine, Paroxetine,<br />
and Sertraline. Bupropion, Mirtazapine, and Razodone, are atypical antidepressants frequently used for<br />
the treatment of <strong>MDD</strong>. <strong>Major</strong> brands of antipsychotics includes Resperidone, Olanzapine, Quetiapine,<br />
Ziprasidone, and Aripiprazole. Global <strong>MDD</strong> treatment market is expected to grow with a healthy CAGR<br />
owing to increase in <strong>MDD</strong> patient pool over the forecast period.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 6
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong><br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Region-wise Outlook<br />
Geographically, North America market is estimated to hold maximum market revenue share in global<br />
<strong>MDD</strong> treatment market owing to increase in number of patients suffering from <strong>MDD</strong>, and advancement<br />
in technology to develop new therapeutic drugs and followed by Europe and Asia-Pacific respectivily. The<br />
market in Asia-Pacific is expected to expand at a significant CAGR over the forecasted period due to<br />
increasing awareness for depression conditions and complications associated with it. <strong>MDD</strong> treatment<br />
market is expected to register healthier CAGR in emerging markets such as India, China, and Brazil<br />
compared to other developed regions in the world.<br />
Browse Full Report@ http://www.futuremarketinsights.com/reports/major-depressive-disordertreatment-market<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Key Players<br />
Key companies operational in <strong>MDD</strong> treatment market are Eli Lilly and Company, Johnson & Johnson,<br />
Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc, Sanofi S.A., Shire plc, Novartis AG,<br />
Janssen Pharmaceutical, Inc., and others.<br />
Click here to<br />
Order a free sample<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 7
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
For media queries, contact the press office at<br />
press@futuremarketinsights.com<br />
For other queries contact:<br />
Hari. T (Sr. Manager - Global Business Development)<br />
Future <strong>Market</strong> Insights: 3rd Floor,<br />
207 Regent Street, London W1B 3HH<br />
T: +44 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com<br />
Thank You<br />
Future <strong>Market</strong> Insights Global & Consulting Private Limited (FMI)<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
8
Change language